Trial Profile
Clostridium butyricum MIYAIRI (CBM588) as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective, Open-Label Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2019
Price :
$35
*
At a glance
- Drugs Clostridium butyricum M588 (Primary) ; Escitalopram; Fluvoxamine; Paroxetine; Sertraline
- Indications Major depressive disorder
- Focus Therapeutic Use
- 01 Oct 2018 New trial record
- 01 Sep 2018 Results published in the Clinical Neuropharmacology